X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs AJANTA PHARMA - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS AJANTA PHARMA NOVARTIS/
AJANTA PHARMA
 
P/E (TTM) x 420.5 20.8 2,023.5% View Chart
P/BV x 29.7 3.6 828.5% View Chart
Dividend Yield % 1.5 1.0 156.5%  

Financials

 NOVARTIS   AJANTA PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-18
AJANTA PHARMA
Mar-19
NOVARTIS/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs7581,422 53.3%   
Low Rs579898 64.5%   
Sales per share (Unadj.) Rs228.4233.5 97.8%  
Earnings per share (Unadj.) Rs31.744.0 72.2%  
Cash flow per share (Unadj.) Rs32.852.2 62.8%  
Dividends per share (Unadj.) Rs10.009.00 111.1%  
Dividend yield (eoy) %1.50.8 192.8%  
Book value per share (Unadj.) Rs297.1255.1 116.5%  
Shares outstanding (eoy) m24.6988.02 28.1%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x2.95.0 58.9%   
Avg P/E ratio x21.126.4 79.8%  
P/CF ratio (eoy) x20.422.2 91.8%  
Price / Book Value ratio x2.24.5 49.5%  
Dividend payout %31.520.5 153.9%   
Avg Mkt Cap Rs m16,505102,081 16.2%   
No. of employees `0000.76.8 9.8%   
Total wages/salary Rs m1,4454,307 33.6%   
Avg. sales/employee Rs Th8,441.33,022.6 279.3%   
Avg. wages/employee Rs Th2,163.6633.4 341.6%   
Avg. net profit/employee Rs Th1,173.1569.1 206.1%   
INCOME DATA
Net Sales Rs m5,63920,554 27.4%  
Other income Rs m1,718211 815.1%   
Total revenues Rs m7,35720,765 35.4%   
Gross profit Rs m-635,664 -1.1%  
Depreciation Rs m25721 3.5%   
Interest Rs m5512 476.7%   
Profit before tax Rs m1,5755,143 30.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7921,273 62.2%   
Profit after tax Rs m7843,870 20.2%  
Gross profit margin %-1.127.6 -4.0%  
Effective tax rate %50.324.8 203.0%   
Net profit margin %13.918.8 73.8%  
BALANCE SHEET DATA
Current assets Rs m9,52211,812 80.6%   
Current liabilities Rs m3,2963,776 87.3%   
Net working cap to sales %110.439.1 282.4%  
Current ratio x2.93.1 92.4%  
Inventory Days Days3777 47.3%  
Debtors Days Days2882 34.8%  
Net fixed assets Rs m4614,398 0.3%   
Share capital Rs m123175 70.4%   
"Free" reserves Rs m7,21322,277 32.4%   
Net worth Rs m7,33622,452 32.7%   
Long term debt Rs m07 0.0%   
Total assets Rs m11,10526,962 41.2%  
Interest coverage x29.5444.3 6.6%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.8 66.6%   
Return on assets %7.614.4 52.5%  
Return on equity %10.717.2 62.0%  
Return on capital %22.223.0 96.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6110,682 0.6%   
Fx outflow Rs m3,6302,102 172.7%   
Net fx Rs m-3,5708,580 -41.6%   
CASH FLOW
From Operations Rs m1,6103,748 43.0%  
From Investments Rs m687-2,228 -30.8%  
From Financial Activity Rs m-2,677-1,475 181.5%  
Net Cashflow Rs m-38045 -839.8%  

Share Holding

Indian Promoters % 0.0 73.8 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 1.6 129.0%  
FIIs % 1.6 7.6 21.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 17.0 126.5%  
Shareholders   41,647 20,968 198.6%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   IPCA LABS  SANOFI INDIA  DR. DATSONS LABS  PROCTER & GAMBLE HEALTH  GSK PHARMA  

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slips below 38,000-Mark; Yes Bank Jumps 9%(12:30 pm)

Share markets in India are presently trading deep in the red as investors were disappointed after the government refused any respite to foreign investors.

Related Views on News

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, AJANTA PHARMA has posted a net profit of Rs 669 m (down 54.6% YoY). Sales on the other hand came in at Rs 5 bn (down 17.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

The Electric Vehicle Disruption is Great News for this Smallcap Stock(Profit Hunter)

Jul 15, 2019

While big auto makers are finding the transition difficult and crying foul, this small cap company is already leading and benefitting from the electric vehicle disruption in the auto sector.

7 Stocks to Profit From an Irreversible Trend(The 5 Minute Wrapup)

Jul 18, 2019

Credit growth is likely to accelerate in India in the next decade. Here's how you can benefit from this megatrend.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jul 22, 2019 12:55 PM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS